

Contents

Abbreviations and acronyms	vii
1. Introduction	1
2. The burden of rabies	1
2.1 Methods for estimating the burden of rabies	2
2.2 Estimated global human burden of rabies	3
2.3 Global burden of rabies	6
2.4 References	8
3. Classification of lyssaviruses	10
3.1 Distinguishing features of lyssaviruses	10
3.2 Criteria for differentiating lyssaviruses	10
3.3 Present structure of the <i>Lyssavirus</i> genus	11
3.4 References	15
4. Pathogenesis	17
4.1 References	19
5. Diagnosis	21
5.1 Standard case definitions for rabies	21
5.2 Clinical diagnosis	22
5.3 Biosafety, sampling and specimen transport for laboratory diagnosis	23
5.4 Laboratory techniques for post-mortem diagnosis of rabies in humans and animals	25
5.5 Techniques for ante-mortem diagnosis of rabies in humans	32
5.6 Measuring antibody response to rabies vaccination in humans	34
5.7 Measuring antibody response to rabies vaccination in animals	35
5.8 Virus identification with molecular techniques: epidemiological considerations	35
5.9 References	36
6. Management of patients before and after death	39
6.1 Management of patients with rabies	39
6.2 Palliative management of patients with rabies	41
6.3 Recommendations for health care personnel and family members of patients with rabies	42
6.4 Survivors of rabies and “aggressive” treatment protocols	43
6.5 Management of the bodies of patients who have died of rabies	44
6.6 Transmission via organ transplantation	45
6.7 References	45

7. Vaccines and rabies immunoglobulins for humans	47
7.1 Vaccine types	47
7.2 WHO prequalification of human rabies vaccines	49
7.3 Requirements for human rabies vaccines	49
7.4 Routes of vaccine administration	50
7.5 Adverse events after active immunization	51
7.6 Duration of immunity	52
7.7 Failure of rabies vaccine and of full post-exposure prophylaxis	52
7.8 Rabies immunoglobulins	52
7.9 References	54
8. Prevention of human rabies	57
8.1 General considerations	57
8.2 Pre-exposure prophylaxis	58
8.3 Post-exposure prophylaxis	60
8.4 Use of rabies immunoglobulins for passive immunization	68
8.5 Contraindications and precautions to be taken in post-exposure prophylaxis	69
8.6 Supply limitations	70
8.7 Travel to rabies-affected countries and areas and indications for pre-exposure prophylaxis	70
8.8 Education to prevent bites	72
8.9 References	72
9. Prevention and control of rabies in dogs	78
9.1 Case definition of animal rabies	78
9.2 Methods for controlling dog rabies	79
9.3 International movement of animals	89
9.4 Humane dog population management	90
9.5 Vaccination versus sterilization	90
9.6 National programmes for dog rabies control: lessons from the field	91
9.7 References	92
10. Prevention and control of rabies in wild animals	96
10.1 Epidemiology and ecology of rabies in carnivore species	96
10.2 Epidemiology and ecology of rabies in bats	98
10.3 Rabies in rodents	101
10.4 Wildlife species of special concern	101
10.5 Elimination of rabies in wild carnivores	102
10.6 Control of rabies in bats	106
10.7 Other public health measures	107
10.8 References	107

11. Surveillance of rabies	111
11.1 Surveillance systems	112
11.2 Global reporting	117
11.3 References	118
12. Reaching zero human deaths from rabies	120
12.1 Core elements of validation, verification and rabies-freedom	122
12.2 Validation of zero human deaths from rabies	123
12.3 Verification of interruption of rabies transmission	124
12.4 References	124
13. Global and regional activities on rabies	125
13.1 WHO global and regional activities	125
13.2 Examples of activities by partners	129
13.3 References	134
14. Research	137
14.1 Improve programmatic delivery of rabies interventions	137
14.2 Improve the quality and availability of data on rabies	139
14.3 Evidence and new tools to improve the prevention and management of rabies	139
14.4 References	140
15. Concluding remarks	141
16. Acknowledgements	141
Annexes	142
Annex 1	
List of participants	142
Annex 2	
Record form for cases of possible exposure to rabies	146
Annex 3	
Human rabies vaccines and producers worldwide, as of August 2017	148
Annex 4	
Four steps for replacing nerve tissue vaccine by modern rabies vaccines produced on cell culture or embryonated eggs	150
Annex 5	
Rabies immunoglobulin (RIG) products and producers worldwide, as of August 2017	151

Annex 6		
	Technique for intradermal administration of rabies vaccine and precautions to be taken	153
Annex 7		
	Sites for intramuscular and intradermal administration of human rabies vaccine	155
Annex 8		
	Recommended post-exposure prophylaxis according to type of exposure	156
Annex 9		
	Suggested rabies vaccination certificates for humans	157
Annex 10		
	Currently available oral rabies vaccine products	159
Annex 11		
	Verbal autopsy questionnaire	160
Annex 12		
	Animal bite investigation form	171
Annex 13		
	WHO data collection template	174
Annex 14		
	Template dossier for validation and verification	175
Annex 15		
	WHO collaborating centres on rabies, neurovirology, viruses, viral zoonoses and zoonosis control	182